Company Overview and News

0
Cape Lambert Resources engineering study supports low-cost cobalt operation

2018-07-16 proactiveinvestors.com.au
Cape Lambert Resources Ltd (ASX:CFE) has received a completed engineering study for a leaching plant at the Kipushi Cobalt-Copper Tailings Project in the Democratic Republic of Congo (DRC).
CFE CMULF

0
Cape Lambert Resources attracts more funds for cobalt-copper project

2018-07-13 proactiveinvestors.com.au
Cape Lambert Resources Ltd (ASX:CFE) has raised $318,000 in a share placement to sophisticated and professional investors priced at 3 cents per share.
CFE CMULF

0
Cape Lambert Resources attracts new capital to advance cobalt-copper project in DRC

2018-06-29 proactiveinvestors.com.au
Cape Lambert Resources Limited (ASX:CFE) has in five days completed two placements of shares at 3 cents and 4 cents each to raise $790,000 in cash and to settle $134,800 due to creditors of the company.
CFE CMULF

0
Cape Lambert Resources board member doubles shareholding

2018-05-31 proactiveinvestors.com.au
Cape Lambert Resources Ltd (ASX:CFE) has had non-executive director Stefan Müller buy 500,000 shares in the company through on-market trades.
CFE CMULF

0
Cape Lambert Resources director buys shares on market

2018-04-16 proactiveinvestors.com.au
Cape Lambert Resources Ltd (ASX:CFE) has received a vote of confidence from its most recently appointed board member, non-executive director Stefan Müller.
CFE CMULF

0
Cape Lambert seeing ‘extreme’ interest from potential offtakers for Kipushi concentrate

2018-04-06 proactiveinvestors.com.au
Tony Sage, executive chairman for Cape Lambert Resources Ltd (ASX:CFE) speaks to Proactive Investors from Mines and Money Asia, where sentiment is buoyant on cobalt.
CFE CMULF

1
Cape Lambert set to provide shareholders "great value over next 12 - 18 months"

2018-04-06 proactiveinvestors.com.au
Tony Sage, executive chairman for Cape Lambert Resources Ltd (ASX:CFE) speaks to Proactive Investors from Mines and Money Asia, where sentiment is buoyant on cobalt.
CFE CMULF

0
Cape Lambert identifies potential high-recovery pathway at cobalt copper tailings project, shares up

2018-03-27 proactiveinvestors.com.au
Cape Lambert Resources Ltd (ASX:CFE) has received results from test work completed at the Kipushi Cobalt-Copper Tailings Project in the Democratic Republic of Congo.
CFE CMULF

0
Cape Lambert identifies potential high-recovery pathway at cobalt copper tailings project

2018-03-26 proactiveinvestors.com.au
Cape Lambert Resources Ltd (ASX:CFE) has received results from test work completed at the Kipushi Cobalt-Copper Tailings Project in the Democratic Republic of Congo.
CFE CMULF

1
Fe Limited hits high-grade copper at DRC project supported by shallow cobalt

2018-03-14 proactiveinvestors.com.au
Fe Limited (ASX:FEL) has received further high-grade copper results supported by cobalt credits from the Kasombo Copper-Cobalt Project in the Democratic Republic of Congo (DRC).
FEL CFE CMULF

1
Cape Lambert Resources leveraged to high-grade copper hits at DRC project

2018-03-14 proactiveinvestors.com.au
Cape Lambert Resources Limited (ASX:CFE) is leveraged to further high-grade copper results from Fe Limited’s (ASX:FEL) Kasombo Copper-Cobalt Project in the Democratic Republic of Congo (DRC).
FEL CFE CMULF

0
Cape Lambert Resources seeks $2 million in placement funds for cobalt-copper exploration

2018-03-12 proactiveinvestors.com.au
Cape Lambert Resources Limited (ASX:CFE) aims to raise up to $2 million in a placement to sophisticated and professional investors.
CFE CMULF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:CFE / CAPE LAMBERT RESOURCES LIMITED on message board site Silicon Investor.

AGC Americau0027s Gold Corporation/ (AGA, AGCFF, AGCFE)